HEM Pharma
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
HEM Pharma develops microbiome-based health and skincare products, using the community of microorganisms that naturally live in and on the human body to create therapeutic candidates and functional cosmetics.
Its products target consumers and patients seeking gut-health solutions and science-backed skincare, and it is listed on KOSDAQ, South Korea's tech and small-cap exchange. The company's portfolio spans live biotherapeutic drug candidates in clinical development and a dermocosmetic line that combines dermatology science with cosmetic formulation, including proprietary ingredients such as a peach-derived probiotic strain.
Summary is AI-generated and may contain errors · figures from DART filings
HEM Pharma holds a proprietary in-house culture technology called PMAS, which it uses to simulate and study how individual microbiomes interact with drug and cosmetic candidates.
HEM Pharma in five facts
What does HEM Pharma do?
HEM Pharma develops microbiome-based health and skincare products, using the community of microorganisms that naturally live in and on the human body to create therapeutic candidates and functional cosmetics.
Where is HEM Pharma listed and in which sector?
HEM Pharma (Korean name: HEM파마) trades under KRX code 376270 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is HEM Pharma?
Its market capitalisation was US$162.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were HEM Pharma's latest annual revenue and operating profit?
For fiscal year 2025, HEM Pharma reported revenue of US$9.8M, an operating loss of US$11.8M and a net loss of US$17.9M, per its annual report on DART (data retrieved from DART on 2026-06-03). Revenue was down 13.9% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-03
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- [Amended] Supply contract signed
HEM Pharma updated a previously disclosed supply contract with access business group, now worth US$3.45M, about 35.63% of its recent annual revenue, running through Feb 2027.
Supply contract · Sep 9 · 3 versions - Material event report (convertible bonds)
HEM Pharma disclosed convertible bonds to raise US$38M, about 22.4% of its market value.
Capital raise · Aug 6 - Decision to acquire shares/equity in another company
HEM Pharma disclosed an acquisition of Nice Health Device Corporation Co., Ltd., worth US$1.25M.
M&A · Jun 19 - [Amended] Material event report (convertible bonds)
HEM Pharma updated the terms of convertible bonds to raise US$10.3M, about 6.6% of its market value.
Capital raise · Jun 19 - Supply contract signed
HEM Pharma disclosed a supply contract with HEM Pharma Japan Inc., worth US$1.4M, about 16.06% of its recent annual revenue, running through May 2027.
Supply contract · May 14 - [Amended] Material event report (spin-off)M&A · Mar 27
- [Amended] Material event report (spin-off)M&A · Mar 6
- Material event report (spin-off)M&A · Mar 6
- Supply contract signed
HEM Pharma disclosed a supply contract with HEM Pharma Japan Inc., worth US$4.98M, about 47.68% of its recent annual revenue, running through Feb 2027.
Supply contract · Feb 24 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
HEM Pharma reported consolidated results for FY2025: revenue of US$9M (−13.57% year on year), an operating loss of US$10.7M and a net loss of US$16.3M.
Earnings · Feb 20